The Committee for Medicinal Products for Human Use recommends authorisation for people aged six months and over. Data show that the updated vaccine generates an improved immune response against currently prevalent variants such as XFG and NB.1.8.1. The European Commission will now decide on the final authorisation. Pfizer and BioNTech have already started production in order to be able to deliver in time for the autumn and winter season. The vaccine is based on BioNTech's mRNA technology and builds on more than one billion doses administered worldwide. With the adaptation to LP.8.1, the companies aim to ensure the effectiveness of vaccination campaigns and strengthen protection against new virus variants.
Press release "BioNTech" from 25/07/2025
